Research programme: fluorine-based therapeutics/radiolabelled diagnostics - OcuTerra Therapeutics
Alternative Names: SF 0034Latest Information Update: 31 Jul 2026
At a glance
- Originator SciFluor Life Sciences
- Developer National Institute of Neurological Disorders and Stroke; OcuTerra Therapeutics
- Class Fluorine compounds; Radiopharmaceutical diagnostics
- Mechanism of Action GABA A receptor agonists; Integrin alphaVbeta3 antagonists; KCNQ potassium channel agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Amyotrophic lateral sclerosis; Partial epilepsies; Tinnitus
Most Recent Events
- 03 May 2024 Discontinued - Preclinical for Age-related macular degeneration in USA (Ophthalmic)
- 03 May 2024 Discontinued - Preclinical for Partial epilepsies (Diagnosis) in USA (PO)
- 03 May 2024 Discontinued - Preclinical for Partial epilepsies in USA (PO)